AgomAb Therapeutics NV (AGMB) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ARS Pharmaceuticals is the larger company by market cap ($433.6 million vs $433.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | SPRY |
|---|---|---|
| Share price | $8.80 | $4.36 |
| Market cap | $433.38M | $433.59M |
| 1-day change | -0.45% | +1.51% |
| YTD return | — | -62.58% |
| 1-year return | — | -57.79% |
| 5-year return | — | -55.78% |
| EPS (TTM) | $-2.08 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $13.15 |
| 52-week low | $7.97 | $3.99 |
| Distance from 52-week high | -50.62% | -66.84% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +328.07% | +416.06% |
| Average volume | 137.04K | 1.86M |
| Shares outstanding | 49.25M | 99.45M |
| Employees | 62 | 195 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 62 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 195 employees
AGMB vs SPRY FAQ
Which is bigger, AgomAb Therapeutics NV or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $433.59M compared with $433.38M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and ARS Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for AgomAb Therapeutics NV and Biotechnology: Pharmaceutical Preparations for ARS Pharmaceuticals.